Steven Cohen Nuvation Bio Inc. Transaction History

Point72 Asset Management, L.P.

$36.6 Billion
Q3 2024

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 276,714 shares of NUVB stock, worth $763,730. This represents 0.0% of its overall portfolio holdings.

Number of Shares

276,714

Holding current value

$763,730

% of portfolio

0.0%

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$2.3 - $3.83 $636,442 - $1.06 Million	276,714 New	276,714 $636,000
Q1 2023 May 15, 2023	BUY	$1.6 - $2.48 $60,316 - $93,491	37,698 New	37,698 $62,000
Q2 2022 Aug 15, 2022	BUY	$3.24 - $5.85 $934,092 - $1.69 Million	288,300 New	288,300 $934,000
Q4 2021 Feb 14, 2022	SELL	$7.75 - $10.05 $1.18 Million - $1.53 Million	-152,300 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$7.78 - $10.0 $1.18 Million - $1.52 Million	152,300 New	152,300 $1.51 Million

Others Institutions Holding NUVB

# of Institutions

158

Shares Held

157M

Call Options Held

3.2K

Put Options Held

98.7K

View Full List

About Nuvation Bio Inc.

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $600M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

More about NUVB

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account